>
Fa   |   Ar   |   En
   Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population  
   
نویسنده Henríquez-Hernández L A ,Valenciano A ,Foro-Arnalot P ,Álvarez-Cubero M J ,Cozar J M ,Suárez-Novo J F ,Castells-Esteve M ,Fernández-Gonzalo P ,De-Paula-Carranza B ,Ferrer M ,Guedea F ,Sancho-Pardo G ,Craven-Bartle J ,Ortiz-Gordillo M J ,Cabrera-Roldán P ,Rodríguez-Melcón J I ,Herrera-Ramos E ,Rodríguez-Gallego C ,Lara P C
منبع prostate cancer and prostatic diseases - 2016 - دوره : 19 - شماره : 1 - صفحه:28 -34
چکیده    Background:novel predictors of prognosis and treatment response for prostate cancer (pca) are required to better individualize treatment. single-nucleotide polymorphisms (snps) in four genes directly (xrcc5 (x-ray repair complementing defective repair in chinese hamster cells 5) and xrcc6 (x-ray repair complementing defective repair in chinese hamster cells 6)) or indirectly (parp1 and major vault protein (mvp)) involved in non-homologous end joining were examined in 494 spanish pca patients.methods:a total of 22 snps were genotyped in a biotrove openarray nt cycler. clinical tumor stage, diagnostic psa serum levels and gleason score at diagnosis were obtained for all participants. genotypic and allelic frequencies were determined using the web-based environment snpator.results:(xrcc6) rs2267437 appeared as a risk factor for developing more aggressive pca tumors. those patients carrying the gg genotype were at higher risk of developing bigger tumors (odds ratio (or)=2.04, 95% confidence interval (ci) 1.26–3.29, p=0.004), present higher diagnostic psa levels (or=2.12, 95% ci 1.19–3.78, p=0.011), higher gleason score (or=1.65, 95% ci 1.01–2.68, p=0.044) and d’amico higher risk tumors (or=2.38, 95% ci 1.24–4.58, p=0.009) than those patients carrying the cc/cg genotypes. those patients carrying the (mvp) rs3815824 tt genotype were at higher risk of presenting higher diagnostic psa levels (or=4.74, 95% ci 1.40–16.07, p=0.013) than those patients carrying the cc genotype. when both snps were analyzed in combination, those patients carrying the risk genotypes were at higher risk of developing d’amico higher risk tumors (or=3.33, 95% ci 1.56–7.17, p=0.002).conclusions:we believe that for the first time, genetic variants at xrcc6 and mvp genes are associated with risk of more aggressive disease, and would be taken into account when assessing the malignancy of pca.
آدرس Hospital Universitario de Gran Canaria Dr. Negrín, Radiation Oncology Department, Spain. Instituto Canario de Investigación del Cáncer, Spain. Universidad de Las Palmas de Gran Canaria, Spain, Instituto Canario de Investigación del Cáncer, Spain, Hospital de la Esperanza, Radiation Oncology Department, Spain, Universidad de Granada, Legal Medicine and Toxicology Department, Laboratory of Genetic Identification, Spain. Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research, Spain, Hospital Universitario Virgen de las Nieves, Department of Urology, Spain, L'Hospitalet de Llobregat, Department of Urology, Spain, L'Hospitalet de Llobregat, Department of Urology, Spain, Radiation Oncology Department, Onkologikoa, Spain, Radiation Oncology Department, Onkologikoa, Spain, Institut de Recerca Hospital del Mar (IMIM), Health Services Research Group, Spain, L'Hospitalet de Llobregat, Department of Radiation Oncology, Spain, Hospital de la Santa Creu i Sant Pau, Radiation Oncology Department, Spain, Hospital de la Santa Creu i Sant Pau, Radiation Oncology Department, Spain, Hospital Universitario Virgen del Rocío, Radiation Oncology Department, Spain, Hospital Universitario Virgen del Rocío, Radiation Oncology Department, Spain, Hospital Universitario de Gran Canaria Dr. Negrín, Radiation Oncology Department, Spain. Instituto Canario de Investigación del Cáncer, Spain, Hospital Universitario de Gran Canaria Dr. Negrín, Department of Immunology, Spain. Universidad de Las Palmas de Gran Canaria, Department of Medical and Surgical Sciences, Spain, Hospital Universitario de Gran Canaria Dr. Negrín, Department of Immunology, Spain, Hospital Universitario de Gran Canaria Dr. Negrín, Radiation Oncology Department, Spain. Instituto Canario de Investigación del Cáncer, Spain. Universidad de Las Palmas de Gran Canaria, Spain
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved